LENSAR Inc. (LNSR)
LENSAR Inc. (LNSR) Stock Price, Analysis & Data
Keine Daten verfügbar
| Geld | 6.14 |
| Marktkapitalisierung | 100.74 Mio |
| Umsatz (TTM) | 60.26 Mio |
| Nettogewinn (TTM) | 34.7 Mio |
| Beta | n/a |
| EPS (ttm) | 0.2 |
| KGV (TTM) | 41 |
| Forward-KGV | -11.55 |
| KBV (TTM) | 6.75 |
| KUV (TTM) | 1.67 |
| Earnings Date | Nov 12, 2026 |
| Brief | 8.18 |
| Volumen | 263,460 |
| Ø Vol. (20D) | 106,617 |
| Eröffnung | 8.72 |
| Vortagesschluss | 8.27 |
| Tagesspanne | 8.09 - 8.74 |
| 52-Wk Range | 4.95 - 12.96 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über LNSR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual out...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von LENSAR 58.44 Mio, ein Anstieg von 9.24% im Vergleich zum Vorjahr (53.49 Mio). Der Gewinn lag bei -34.28 Mio, ein Anstieg von 9.16 %.
FinanzberichteGewinnüberraschung
Analysten erwarten einen Umsatz von ... Upgrade
vor 2 Monaten · Simply Wall St.
How The LENSAR (LNSR) Story Is Shifting After The Failed Deal And New $10 TargetThe analyst price target for LENSAR has been set at $10, compared with an unchanged fair value estimate of $8.50 in the updated model. Bullish commentary links this $10 target to expectations that pro...